Martínez López, AngélicaGarcía Casas, AnaBragado Domingo, PalomaOrimo, AkiraCastañeda-Saucedo, EduardoCastillo Lluva, Sonia2023-06-162023-06-162021-08-190304-383510.1016/j.canlet.2021.08.014https://hdl.handle.net/20.500.14352/4678CRUE-CSIC (Acuerdos Transformativos 2021)Cancer-associated fibroblasts (CAFs) are highly abundant stromal components in the tumour microenvironment. These cells contribute to tumorigenesis and indeed, they have been proposed as a target for anti-cancer therapies. Similarly, targeting the Rho-GTPase RAC1 has also been suggested as a potential therapeutic target in cancer. Here, we show that targeting RAC1 activity, either pharmacologically or by genetic silencing, increases the pro-tumorigenic activity of CAFs by upregulating IL-1β secretion. Moreover, inhibiting RAC1 activity shifts the CAF subtype to a more aggressive phenotype. Thus, as RAC1 suppresses the secretion of IL-1β by CAFs, reducing RAC1 activity in combination with the depletion of this cytokine should be considered as an interesting therapeutic option for breast cancer in which tumour cells retain intact IL-1β signalling..engAtribución-NoComercial-SinDerivadas 3.0 Españajournal articlehttps://doi.org/10.1016/j.canlet.2021.08.014open access577.1Stromal RAC1Cancer-associated fibroblastsBreast cancerIL-1βQuímicaBioquímica (Química)23 Química